

DAFTAR PUSTAKA

1. Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. *Nat Rev Neurol*. 2019;15(11):671–83.
2. Bhatia VD, Khant PB, Vyshnavee I, Shiyaf M, Thunga G, Gorthi SP, et al. Identification of factors affecting outcomes in patients with Guillain Barre syndrome. *Med Pharm reports*. 2022 Oct;95(4):400–9.
3. Strasser E. Principles of Therapeutic Apheresis in Neurological Disease. *Transfus Med hemotherapy Off Organ der Dtsch Gesellschaft fur Transfusionsmedizin und Immunhamatologie*. 2023 Apr;50(2):88–97.
4. Ali T, Fakher FHA, Alawir M, Allababidi A, Aya SH. Management of severe pediatric Guillain-Barré syndrome in a low-income country: efficacy and safety of therapeutic plasma exchange in pediatric patients: a retrospective study. *BMC Pediatr*. 2024;24(1):1–15.
5. Laman JD, Huizinga R, Boons G jan, Jacobs BC. Guillain-Barré syndrome: expanding the concept of molecular mimicry. *Trends Immunol*. 2022;43(4):296–308.
6. Jufan AY, Sudadi, Sunantara IGNPM. Manajemen pada pasien sindroma Guillain-Barré di ICU RSUP Dr. Sardjito. *J Komplikasi Anestesi*. 2023;9(2):20–6.
7. Bellanti R, Rinaldi S. Guillain-Barré syndrome: a comprehensive review. *Eur J Neurol*. 2024;31(8):1–15.
8. Masra S, Susanti L, Yulia D. Karakteristik pasien sindrom Guillain-Barré di RSUP Dr. M. Djamil Padang tahun 2020-2023. Padang: Universitas Andalas; 2024;
9. Shang P, Feng J, Wu W, Zhang HL. Intensive care and treatment of severe Guillain–Barré syndrome. *Front Pharmacol*. 2021;12(April):1–17.
10. Shang P, Zhu M, Baker M, Feng J, Zhou C, Zhang HL. Mechanical ventilation in Guillain–Barré syndrome. *Expert Rev Clin Immunol*. 2020;16(11):1053–64.
11. Tewedaj ZD, Huluka DK, Kebede YT, Abebe AT, Hussen MS, Mohammed BD, et al. A retrospective analysis of the clinical profile and factors associated with mortality and poor hospital outcomes in adult Guillain–Barre syndrome patients. *Sci Rep*. 2024;14(1):1–8.
12. Ruiz-Sandoval JL, Salvatella-Gutiérrez AP, López-Valencia G, Chiquete E, Ruiz-Herrera V, Pérez-Gómez HR, et al. Clinical Characteristics and

Predictors of Short-Term Outcome in Mexican Adult Patients with Guillain-Barré Syndrome. *Neurol India*. 2021;69(1):107–14.

13. Faustino P, Coutinho M, Brum M, Medeiros L, Ladeira F. Outcomes in Guillain-Barré syndrome following a second therapeutic cycle – a single-centre retrospective observational study. *J Neurol Sci*. 2022;441:1–3.
14. Savithri Nandeesha S, Kasagga A, Hawrami C, Ricci E, Hailu KT, Salib K, et al. Treatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barré Syndrome Management: A Systematic Review. *Cureus*. 2024 Mar;16(3):e57066.
15. Ruiz DD, Miguel FFS, Molina FJG de, Úbeda-Iglesias A, Pérez AN, Forés RJ. Plasmapheresis and other extracorporeal filtration techniques in critical patients. *Med Intensiva English Ed*. 2017;41(3):174–87.
16. Błasiak M, Korohoda P, Zachwieja K, Drożdż D, Gergont A, Madej-Świątkowska K, et al. Safety and efficacy of therapeutic plasma exchange in pediatric neuro-immunological diseases. *Adv Med Sci*. 2025;70(1):86–93.
17. Ullah W, Ali H, Muhammad Y, Ullah N, Khalil I, Ahmad S, et al. Evaluating the efficacy and cost-effectiveness of plasmapheresis and intravenous immunoglobulin in acute Guillain-Barre syndrome management in emergency departments. 2024;16(10):1–8.
18. Aninditha T, Harris S, Wiratman W, editors. *Buku ajar neurologi*. 2nd ed. Jakarta: EGC; 2022.
19. Lee K, editor. *The neuro ICU book*. New York: The McGraw-Hill Companies; 2012.
20. Parry GJ, Steinberg JS. *Guillain Barre syndrome from diagnosis to recovery*. Shulman LM, editor. New York: American Academy Of Neurologi; 2007.
21. Hakim M, Gunadharma S, Basuki M, editors. *Pedoman tatalaksana GBS, CIDP, MG, dan imunoterapi*. 1st ed. Jakarta: Perdossi; 2018.
22. Van Doorn PA, Van den Bergh PYK, Hadden RDM, Avau B, Vankrunkelsven P, Attarian S, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain–Barré syndrome. *Eur J Neurol*. 2023;30(12):3646–74.
23. Bragazzi NL, Kolahi AA, Nejadghaderi SA, Lochner P, Brigo F, Naldi A, et al. Global, regional, and national burden of Guillain–Barré syndrome and its underlying causes from 1990 to 2019. *J Neuroinflammation*. 2021;18:1–11.
24. Xu L, Zhao C, Bao Y, Liu Y, Liang Y, Wei J, et al. Variation in worldwide incidence of Guillain-Barré syndrome: a population-based study in urban

- China and existing global evidence. *Front Immunol.* 2024;15:1–10.
25. Hiew FL, Thit WM, Alexander M, Thirugnanam U, Siritho S, Tan K, et al. Consensus recommendation on the use of therapeutic plasma exchange for adult neurological diseases in Southeast Asia from the Southeast Asia therapeutic plasma exchange consortium. *J Cent Nerv Syst Dis.* 2021;13:1–12.
26. Wachira VK, Farinasso CM, Silva RB, Peixoto HM, de Oliveira MRF. Incidence of Guillain-Barré syndrome in the world between 1985 and 2020: a systematic review. *Glob Epidemiol.* 2023;5:1–24.
27. Koike H, Chiba A, Katsuno M. Emerging infection, vaccination, and Guillain-Barré syndrome: a review. *Neurol Ther.* 2021;10:523–37.
28. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. *Lancet.* 2021;397:1214–28.
29. Wijdicks EFM. The practice of emergency and critical care neurology. 2nd ed. New York: Oxford University Press; 2016.
30. Rahman RS, Bauthman MS, Alanazi AM, Alsillah NN, Alanazi ZM, Almuahysin MI, et al. Guillain-Barré syndrome: pathophysiology, etiology, causes, and treatment. *Int J Community Med Public Heal.* 2021;8(7):3624–8.
31. Hughes RAC. Guillain-Barré syndrome: History, pathogenesis, treatment, and future directions. *Eur J Neurol.* 2024;31:1–7.
32. Pascual-Goñi E, Caballero-Ávila M, Querol L. Antibodies in autoimmune neuropathies: what to test, how to test, why to test. *Neurology.* 2024;103(4):1–10.
33. Elendu C, Osamuyi EI, Afolayan IA, Opara NC, Chinedu-Anunaso NA, Okoro CB, et al. Clinical presentation and symptomatology of Guillain-Barré syndrome: A literature review. *Medicine (Baltimore).* 2024 Jul;103(30):e38890.
34. Rao GSU. Critical care in Guillain-Barré syndrome. *J Neuroanaesth Crit Care.* 2024;11(2):77–85.
35. Rae-Grant AD, John S, Morren JA, Fernandez HH, editors. Ultimate review for the neurology boards. 3rd ed. New York: Demos Medical Publishing; 2017.
36. Kurniawan M, Ganiem AR, Wiratman W, editors. Pedoman praktik klinis neurologi 2023. Jakarta: Perdossi; 2023.

37. Yao J, Zhou R, Liu Y, Lu Z. Progress in Guillain-Barré syndrome immunotherapy—A narrative review of new strategies in recent years. *Hum Vaccin Immunother* [Internet]. 2023;19(2). Available from: <http://dx.doi.org/10.1080/21645515.2023.2215153>
38. Verboon C, Van Den Berg B, Cornblath DR, Venema E, Gorson KC, Lunn MP, et al. Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. *J Neurol Neurosurg Psychiatry*. 2019;0:1–9.
39. Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, Van den Berg B, Doets AY, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. *Lancet Neurol*. 2021;20:275–83.
40. Lin J, Gao Q, Xiao K, Tian D, Hu W, Han Z. Efficacy of therapies in the treatment of Guillain-Barre syndrome: A network meta-analysis. *Medicine (Baltimore)*. 2021 Oct;100(41):e27351.
41. Busl KM, Fried H, Muehlschlegel S, Wartenberg KE, Rajajee V, Alexander SA, et al. Guidelines for neuroprognostication in adults with Guillain-Barré syndrome. *Neurocrit Care*. 2023;1–20.
42. Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing Committee of the American Society for Apheresis: the ninth special issue. *J Clin Apher*. 2023;38:77–278.
43. Liubchak V V., Khomenko LM, Kovalishyn MP, Ilyina V V., Smilianov VA, Sikora V V., et al. Medical and economic analysis of the choice of therapeutic plasmapheresis method to optimize the transfusion care quality. *Wiad Lek*. 2021;74(10):2466–70.
44. Ring A, Sieber WA, Studt JD, Schuepbach RA, Ganter CC, Manz MG, et al. Indications and outcomes of patients receiving therapeutic plasma exchange under critical care conditions: a retrospective eleven-year single-center study at a tertiary care center. *J Clin Med*. 2023;12:1–17.
45. Altobelli C, Anastasio P, Cerrone A, Signoriello E, Lus G, Pluvio C, et al. Therapeutic plasmapheresis: a revision of literature. *Kidney Blood Press Res*. 2022;48:66–78.
46. Abbas M, Robert HM, Mahmood A, Ali N, Ayaz MA. Plasmapheresis in the treatment of guillain-barre syndrome: outcomes and complications. *J Postgr Med Inst*. 2020;34(3):159–63.
47. Albin CSW, Zafar SF, editors. The acute neurology survival guide: a

practical resource for inpatient and ICU neurology. Switzerland: Springer Nature; 2022.

48. Guevara-Silva E, Castro-Suarez S, Caparó-Zamalloa C, Cortez-Escalante J, Meza-Vega M. Clinical Characteristics And Plasma Exchange Response In Guillain-Barré Patients. *Rev Peru Med Exp Salud Publica*. 2021;38(1):89–94.
49. Bano S, Sardar Z, Ahmar M, Liaquat S, Shafiq B, Numan A. Clinical Spectrum and Outcome of Guillain-Barré Syndrome with Plasmapheresis. *Indian J Med Spec*. 2022;13(4):226–30.
50. Singh AM, Sawardekar VM, Jaiswal A, Kale MM. Clinical, laboratory, and electrophysiological presentations and treatment modalities in Guillain-Barré syndrome: A prospective study. *J Intern Med India*. 2024;17:7–12.
51. Mohy-Eldeen ZM, Ahmad AR, Mahran HH, Saad K. Comparative study of various therapeutic modalities for guillain barré syndrome in assiut university children hospital. *Turk J Pediatr*. 2020;62(6):962–9.
52. Iacono S, Schirò G, Salemi G, Scirè E, Aridon P, Melfa M, et al. Efficacy and Safety of Rescue Treatment with Plasma Exchange in Patients with Acute Inflammatory Neurological Disorders: A Single Center Experience. *Neurol Int*. 2024;16(4):761–75.
53. Khosa NA, Zarkoon AUH, Ibrahim IA, Zarak MS, Essa SM, Mumtaz T. Plasma-exchange therapy in acute immune-mediated neuropathy: Effects on muscle strength and functional outcomes. *Rom J Neurol* [Internet]. 2024;23(2):160–5.
54. Nieto-Aristizábal I, Vivas AJ, Ruiz-Montaña P, Aragón CC, Posso-Osorio I, Quiñones J, et al. Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease. *Autoimmune Dis*. 2020;2020:1–6.
55. Mishra AP, Sahoo SK, Kanungo G, Sahoo LK, Mishra S, Mishra C. Therapeutic Plasma Exchange in Neurological Conditions: An Observation from the Eastern Part of India. *Ann Afr Med*. 2024 Oct;23(4):649–55.
56. Sang-Wook Y, Lee JH, Hong JM, Choi YC, Park HJ. Incidence, Disability, and Mortality in Patients With Guillain-Barré Syndrome in Korea: A Nationwide Population-Based Study. *J Clin Neurol*. 2022;18(1):48–58.
57. McCombe PA, Hardy TA, Nona RJ, Greer JM. Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis. *Front Immunol*. 2022;13:1–23.
58. Grisold A, Schober B, Zimprich F, Zulehner G, Cetin H, Rath J, et al. Real-

world treatment of adult patients with Guillain-Barré syndrome over the last two decades. *Sci Rep.* 2021;11(1):1–9.

59. P Zheng, Liu L, Yu F. Incidence of Guillain-Barré syndrome (GBS) in China: a national population-based study Preprint. 2021;(9):1–32.
60. Hagen KM, Ousman SS. The Neuroimmunology of Guillain-Barré Syndrome and the Potential Role of an Aging Immune System. *Front Aging Neurosci.* 2021;12:1–19.
61. Hardi FR. Karakteristik Pasien Sindrom Guillain Barre di Indonesia Tinjauan Sistematis. *Univ Pembang Nas Veteran Jakarta.* 2021;5–24.
62. Agarwal E, Bhagat A, Srivastava K, Thakore B, Jagtap S, Kalane U, et al. Clinical and Electrophysiological Factors Predicting Prolonged Recovery in Children with Guillain-Barré Syndrome. *Indian J Pediatr.* 2022;89(5):452–8.
63. El-Sayed Mukhtar Y, Ibrahim Mnechie T, Kawashti Gad H, Ahmed Zaki M. Predictors of Response To Plasmapheresis in Autoimmune Neuropathies. *Al-Azhar Med J.* 2021;50(2):1365–74.
64. Ahmed N, Ahmad I, Siddiqi FA, Nawaz KH, Liaqat J, Ahmad F. Complications of Therapeutic Plasmapheresis in Patients with Neurologic Diseases at A Tertiary Care Hospital. *Life Sci.* 2024;5(2):07.
65. Kazmi SS, Alamgir W, Hashmat A, Yousaf A, Nawaz KH, Hassan Z. Plasmapheresis in Neurological Disorders: Frequency and Type of Adverse Effects Associated with this Procedure in Atertiary Care Hospital in Pakistan. 2022;72:389–92.
66. Wells, G., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P., 2011. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute.
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. diakses September 2025